845960-13-6

Basic information

• Product Name: 1H-Imidazo[4,5-b]pyridine, 2-(4-fluorophenyl)-7-methyl-
• CAS NO: 845960-13-6
• Molecular Formula: C13H10FN3
• Molecular Weight: 227.241
• Mol File: 845960-13-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Imidazo[4,5-b]pyridine, 2-(4-fluorophenyl)-7-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazo[4,5-b]pyridine, 2-(4-fluorophenyl)-7-methyl-(845960-13-6)
• EPA Substance Registry System: 1H-Imidazo[4,5-b]pyridine, 2-(4-fluorophenyl)-7-methyl-(845960-13-6)

Safety Data

• Hazardous Substances Data: 845960-13-6(Hazardous Substances Data)

Upstream product

• 6635-86-5 2-amino-4-methyl-3-nitropyridine 
• 459-57-4 4-fluorobenzaldehyde 
• 53929-59-2 4-methyl-2,3-diaminopyridine 
• 456-22-4 4-Fluorobenzoic acid 

Downstream Products

• 1384183-30-5 C₂₀H₁₅F₂N₅O 
• 1584652-25-4 (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-2-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridine-7-carboxamide 
• 944746-09-2 methyl 2-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridine-7-carboxylate 

Relevant articles and documents

Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)

Fibroblast activation protein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV). It has been convincingly linked to multiple disease states involving remodeling of the extracellular matrix. FAP inhibition is investigated as a therapeutic option for several of these diseases, with most attention so far devoted to oncology applications. We previously discovered the N-4-quinolinoyl-Gly-(2S)-cyanoPro scaffold as a possible entry to highly potent and selective FAP inhibitors. In the present study, we explore in detail the structure-activity relationship around this core scaffold. We report extensively optimized compounds that display low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP) the log D values, plasma stabilities, and microsomal stabilities of selected compounds were found to be highly satisfactory. Pharmacokinetic evaluation in mice of selected inhibitors demonstrated high oral bioavailability, plasma half-life, and the potential to selectively and completely inhibit FAP in vivo.

IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The inventive imidazopyridine derivative can be used in a pharmaceutical composition for preventing or treating diseases such as diabetes, obesity, dementia, cancer, and inflammation, since it can efficiently inhibit the activities of several protein kina